8-K: Coherus BioSciences Announces Preliminary 2024 Results and UDENYCA Franchise Divestiture

Coherus BioSciences expects 2024 net revenues between $255M and $260M and plans to divest its UDENYCA franchise for up to $558.4M.

Summary

• Coherus BioSciences announced preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2024.
• The company expects total year net revenues to be between $255 million and $260 million.
• Q4 expected net revenues are projected to be $49 million to $54 million.
• LOQTORZI sales are expected to be $7 million to $8 million, showing over 20% quarter-over-quarter growth since its launch in Q1.
• UDENYCA sales are expected to be $42 million to $47 million, indicating strong demand after a temporary supply interruption.
• Year-end cash, cash equivalents, and investments are expected to be around $125 million.
• Coherus plans to divest the UDENYCA franchise for up to $558.4 million.
• The proceeds from the divestiture will be used to repay the company's $230 million convertible notes due in April 2026.
• Post-close cash runway is projected to exceed two years, past key data readouts expected in 2026.
• All three presentations of UDENYCA are being temporarily allocated due to strong demand in Q4 2024 and into Q1 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the expected revenue figures, strong growth of LOQTORZI, and the strategic divestiture to improve the company's financial position. However, the preliminary nature of the results and temporary supply allocation of UDENYCA temper the overall sentiment.

Positives

• Expected net revenues for 2024 are between $255 million and $260 million.
• LOQTORZI sales show strong growth, exceeding 20% quarter-over-quarter since its launch.
• UDENYCA sales indicate strong demand despite a temporary supply interruption.
• The divestiture of the UDENYCA franchise will provide significant capital to repay debt and extend the cash runway.
• The company projects a cash runway exceeding two years post-divestiture.

Negatives

• The preliminary financial information is unaudited and subject to change.
• UDENYCA presentations are being temporarily allocated due to strong demand, which could indicate supply constraints.

Risks

• The final financial results for 2024 may vary materially from the preliminary unaudited results.
• The closing of the proposed transactions, including the divestiture, is subject to various conditions, including regulatory approvals and shareholder approval.
• Temporary allocation of UDENYCA presentations could impact sales if supply issues persist.

Future Outlook

The company expects to use the proceeds from the UDENYCA franchise divestiture to repay its convertible notes and extend its cash runway beyond two years, past key data readouts expected in 2026.

Industry Context

The announcement reflects Coherus's strategic focus on its core portfolio and strengthening its financial position through divestiture and debt repayment. This is in line with industry trends of companies optimizing their asset portfolios to focus on key growth areas.

Comparison to Industry Standards

• It is difficult to compare Coherus's results directly to industry standards without knowing the specific details of their product portfolio and market segments.
• However, the projected revenue growth for LOQTORZI exceeding 20% QoQ is a positive sign, indicating strong market adoption compared to other recently launched oncology products.
• The divestiture of UDENYCA is a strategic move similar to other pharmaceutical companies divesting non-core assets to focus on higher-growth areas.

Stakeholder Impact

• Shareholders will be impacted by the divestiture and the use of proceeds to repay debt and extend the cash runway.
• Customers may experience temporary allocation of UDENYCA presentations due to strong demand.
• Employees in the UDENYCA franchise may be affected by the divestiture.

Next Steps

• The company plans to release its complete Fourth Quarter and Full Year 2024 Financial Results in March 2025.
• The company will seek shareholder approval for the UDENYCA franchise divestiture.
• The company will work to satisfy customary closing conditions and obtain regulatory approvals for the divestiture.

Key Dates